Prothena/$PRTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Prothena
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Ticker
$PRTA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Dublin, Ireland
Employees
163
ISIN
IE00B91XRN20
Website
Prothena Metrics
BasicAdvanced
$310M
-
-$2.05
-0.08
-
Price and volume
Market cap
$310M
Beta
-0.08
52-week high
$25.42
52-week low
$4.32
Average daily volume
2.2M
Financial strength
Current ratio
9.001
Quick ratio
8.625
Long term debt to equity
1.731
Total debt to equity
2.331
Profitability
EBITDA (TTM)
-137.713
Gross margin (TTM)
-51.68%
Net profit margin (TTM)
-79.94%
Operating margin (TTM)
-100.49%
Effective tax rate (TTM)
4.83%
Revenue per employee (TTM)
$850,000
Management effectiveness
Return on assets (TTM)
-15.49%
Return on equity (TTM)
-23.46%
Valuation
Price to revenue (TTM)
2.243
Price to book
0.71
Price to tangible book (TTM)
0.71
Price to free cash flow (TTM)
-2.369
Free cash flow yield (TTM)
-42.22%
Free cash flow per share (TTM)
-242.75%
Growth
Revenue change (TTM)
54.55%
Earnings per share change (TTM)
-36.43%
3-year revenue growth (CAGR)
-11.88%
10-year revenue growth (CAGR)
21.79%
3-year earnings per share growth (CAGR)
15.17%
10-year earnings per share growth (CAGR)
2.87%
What the Analysts think about Prothena
Analyst ratings (Buy, Hold, Sell) for Prothena stock.
Bulls say / Bears say
Prothena's partnership with Novo Nordisk for the development of coramitug in ATTR amyloidosis has progressed to a Phase 2 clinical trial, with topline data expected in the first half of 2025, potentially leading to significant advancements in treatment options. (seekingalpha.com)
The company's collaboration with Roche on prasinezumab for Parkinson's disease has shown potential clinical effects on motor progression, indicating promising developments in their neurodegenerative disease pipeline. (panabee.com)
Prothena's strong cash position of $471.4 million as of December 31, 2024, provides a solid foundation to support ongoing research and development activities without immediate financial constraints. (tradingview.com)
The failure of the Phase 3 AFFIRM-AL trial for birtamimab in AL amyloidosis led to a significant price target reduction by Citizens JMP from $78 to $29, reflecting diminished investor confidence. (finviz.com)
Prothena reported a net loss of $122 million in 2024, following a $147 million loss in 2023, indicating ongoing financial challenges and the potential need for additional capital. (panabee.com)
The company's exploration of a potential sale, as reported in October 2023, suggests strategic uncertainties that could impact long-term growth prospects. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 18 Jun 2025.
Prothena Financial Performance
Revenues and expenses
Prothena Earnings Performance
Company profitability
Prothena News
AllArticlesVideos
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
Business Wire·5 days ago
Why Is Prothena Stock Trading Lower On Tuesday?
Benzinga·3 weeks ago
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prothena stock?
Prothena (PRTA) has a market cap of $310M as of June 20, 2025.
What is the P/E ratio for Prothena stock?
The price to earnings (P/E) ratio for Prothena (PRTA) stock is 0 as of June 20, 2025.
Does Prothena stock pay dividends?
No, Prothena (PRTA) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Prothena dividend payment date?
Prothena (PRTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Prothena?
Prothena (PRTA) has a beta rating of -0.08. This means that it has an inverse relation to market volatility.